

Insulin Delivery Device - Company Evaluation Report, 2025

Market Report | 2025-08-01 | 154 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$2650.00
- Corporate License \$4250.00

Report description:

The Insulin Delivery Devices Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Insulin Delivery Devices. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 240 companies, of which the Top 25 Insulin Delivery Devices Companies were categorized and recognized as quadrant leaders.

Insulin delivery devices such as pens, pen needles, syringes, and pumps are essential tools for diabetes patients to control their blood glucose levels. This dominance is attributed to the increasing preference for insulin pens among diabetic patients due to their ease of use, improved convenience, reduced pain during administration, enhanced dosage accuracy, and improved medication adherence.

The growth of the insulin delivery devices market is primarily driven by the rising prevalence of diabetes, ongoing technological advancements in insulin delivery solutions, and supportive government initiatives coupled with favourable reimbursement policies. These factors collectively contribute to the increasing adoption of insulin delivery devices worldwide.

The 360 Quadrant maps the Insulin Delivery Devices companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Insulin Delivery Devices quadrant. The top criteria for product footprint evaluation included By Type (Insulin Pens, Insulin Pumps, Insulin Pen Needles, Insulin Syringes, Other Insulin Delivery Devices), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), and By End User (Home Care Settings, Hospitals & Clinics, Other End Users).

Key Players

Key players in the Insulin Delivery Devices market include major global corporations and specialized innovators such as Embecta Corp. (US), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Ypsomed (Switzerland), Eli Lilly and Company (US), Tandem Diabetes Care, Inc. (US), Roche Diabetes Care (Switzerland), HTL-STREFA, a subsidiary of MTD Group (Poland), Terumo Corporation (Japan), Eoflow Co., Ltd (South Korea), B. Braun SE (Germany), Haselmeier, a subsidiary of Medmix (Germany), Insulet Corporation (US), Biocon (India), Nipro (Japan), Sooil Developments Co., Ltd (South Korea), Wockhardt (India), MannKind Corporation (US), Medtrum Technologies Inc. (China), CeQur Corporation (Switzerland), Hindustan Syringes & Medical Devices Ltd (India), Sungshim Medical Co., Ltd (South Korea), Debiotech SA (Switzerland), and Jiangsu Delfu Medical Co., Ltd (China). These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Top 3 Companies

Embecta Corp.

Embecta Corp. was established on April 1, 2022, as a spin-off from Becton, Dickinson and Company (BD), inheriting BD's legacy in diabetes care. As a global leader in medical devices, Embecta focuses exclusively on delivering diabetes care solutions aimed at improving patient health and quality of life. Its product portfolio includes a comprehensive range of pen needles, syringes, and safety injection devices. Embecta supports its global operations through a robust manufacturing, commercial, and distribution infrastructure.

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company renowned for its leadership in diabetes care. The company operates through two main business segments: Diabetes and Obesity Care and Rare Disease (formerly known as Biopharm). The company also provides innovative digital tools for diabetes management, including smart insulin pens and Dose Check, a digital application for insulin dose guidance. It maintains a robust global presence, with offices in 80 countries and product distribution spanning over 170 markets, reinforcing its commitment to improving the lives of people living with diabetes and related conditions worldwide.

Ypsomed

Ypsomed is a leading developer and manufacturer of injection and infusion systems for self-medication, with more than 40 years of experience and recognized expertise in diabetes care. The company is an independent industry leader in the production of injection pens for pharmaceutical and biotechnology companies, as well as diabetes-focused products such as insulin pumps, pen needles, and blood glucose monitoring systems.

Table of Contents:

1	INTRODUCTION	13
1.1	MARKET DEFINITION	13
1.2	INCLUSION AND EXCLUSIONS	13
1.3	STAKEHOLDERS	14
2	EXECUTIVE SUMMARY	15
3	MARKET OVERVIEW	19
3.1	INTRODUCTION	19
3.2	MARKET DYNAMICS	19
3.2.1	DRIVERS	20
3.2.1.1	Growth in prevalence of diabetic population	20
3.2.1.2	Technological advancements in insulin delivery devices	21
3.2.1.3	Government support and favorable reimbursement schemes to favor the market growth	23
3.2.2	RESTRAINTS	23
3.2.2.1	High cost and lack of reimbursement in emerging economies	23
3.2.2.2	Needle anxiety in patients to affect growth of pen needles and syringes market	24
3.2.2.3	Oral insulin as alternative drug delivery method	24
3.2.3	OPPORTUNITIES	25
3.2.3.1	Increase in research & development activities and strategic partnerships	25
3.2.3.2	Increase in healthcare expenditure on diabetes care	26
3.2.3.3	Advances in insulin syringe and needle technology	26
3.2.3.4	Mandates pertaining to safety-engineered medical needles	27
3.2.4	CHALLENGES	27
3.2.4.1	Needlestick injuries and misuse of injection pens	27
3.2.4.2	Lack of interoperability among insulin delivery devices	28

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3.3	INDUSTRY TRENDS	29
3.3.1	GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS	29
3.3.2	SYNCHRONIZATION OF SMART INSULIN PENS WITH CONTINUOUS GLUCOSE MONITORING SYSTEMS PROMOTES DIABETES DATA SHARING	30
3.3.3	INCREASE IN NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS	31
3.4	TECHNOLOGY ANALYSIS	31
3.4.1	KEY TECHNOLOGIES	31
3.4.1.1	Automated insulin delivery	31
3.4.2	COMPLEMENTARY TECHNOLOGIES	32
3.4.2.1	Bluetooth	32
3.4.3	ADJACENT TECHNOLOGIES	32
3.4.3.1	Continuous glucose monitoring	32
3.5	KEY CONFERENCES & EVENTS	33
3.6	PATENT ANALYSIS	34
3.6.1	PATENT PUBLICATION TRENDS FOR INSULIN DELIVERY DEVICES	34
3.6.2	JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN INSULIN DELIVERY DEVICES MARKET	34
3.7	ECOSYSTEM MARKET MAP	37
3.8	PORTER'S FIVE FORCES ANALYSIS	39
3.8.1	INTENSITY OF COMPETITIVE RIVALRY	40
3.8.2	BARGAINING POWER OF SUPPLIERS	40
3.8.3	BARGAINING POWER OF BUYERS	40
3.8.4	THREAT OF SUBSTITUTES	41
3.8.5	THREAT OF NEW ENTRANTS	41
3.9	TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS	41
3.10	IMPACT OF AI/GENERATIVE AI ON INSULIN DELIVERY DEVICES MARKET	42
4	COMPETITIVE LANDSCAPE	43
4.1	INTRODUCTION	43
4.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	43
4.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INSULIN DELIVERY DEVICES MARKET	43
4.3	REVENUE ANALYSIS, 2022-2024	45
4.4	MARKET SHARE ANALYSIS, 2024	45
4.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	47
4.5.1	STARS	48
4.5.2	EMERGING LEADERS	48
4.5.3	PERVASIVE PLAYERS	48
4.5.4	PARTICIPANTS	48
4.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	50
4.5.5.1	Company footprint	50
4.5.5.2	Type footprint	51
4.5.5.3	Region footprint	52
4.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	53
4.6.1	PROGRESSIVE COMPANIES	53
4.6.2	RESPONSIVE COMPANIES	53
4.6.3	DYNAMIC COMPANIES	53
4.6.4	STARTING BLOCKS	53
4.6.5	COMPETITIVE BENCHMARKING	55

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.6.5.1 Detailed list of key startups/SMEs, 2024 55
- 4.6.5.2 Competitive benchmarking of key startups/SMEs 56
- ?
- 4.7 BRAND/PRODUCT COMPARISON 57
- 4.8 COMPANY VALUATION & FINANCIAL METRICS 58
 - 4.8.1 FINANCIAL METRICS 58
 - 4.8.2 COMPANY VALUATION 58
- 4.9 R&D ASSESSMENT OF KEY PLAYERS 59
- 4.10 COMPETITIVE SCENARIO 59
 - 4.10.1 PRODUCT LAUNCHES & APPROVALS 59
 - 4.10.2 DEALS 66
 - 4.10.3 EXPANSIONS 72
 - 4.10.4 OTHER DEVELOPMENTS 75
- 5 COMPANY PROFILES 77
 - 5.1 KEY PLAYERS 77
 - 5.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS) 77
 - 5.1.1.1 Business overview 77
 - 5.1.1.2 Products offered 78
 - 5.1.1.3 Recent developments 79
 - 5.1.1.3.1 Product launches and approvals 79
 - 5.1.1.3.2 Deals 79
 - 5.1.1.3.3 Expansions 80
 - 5.1.1.3.4 Other developments 80
 - 5.1.1.4 MnM view 80
 - 5.1.1.4.1 Right to win 80
 - 5.1.1.4.2 Strategic choices 81
 - 5.1.1.4.3 Weaknesses & competitive threats 81
 - 5.1.2 NOVO NORDISK A/S 82
 - 5.1.2.1 Business overview 82
 - 5.1.2.2 Products offered 83
 - 5.1.2.3 Recent developments 84
 - 5.1.2.3.1 Product launches and approvals 84
 - 5.1.2.3.2 Deals 84
 - 5.1.2.3.3 Other developments 86
 - 5.1.2.4 MnM view 87
 - 5.1.2.4.1 Right to win 87
 - 5.1.2.4.2 Strategic choices 87
 - 5.1.2.4.3 Weaknesses & competitive threats 87
 - 5.1.3 MEDTRONIC 88
 - 5.1.3.1 Business overview 88
 - 5.1.3.2 Products offered 89
 - 5.1.3.3 Recent developments 90
 - 5.1.3.3.1 Product launches and approvals 90
 - 5.1.3.3.2 Deals 91
 - 5.1.3.3.3 Expansions 92
 - 5.1.3.3.4 Other developments 92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.3.4 MnM view 92
- 5.1.3.4.1 Right to win 92
- 5.1.3.4.2 Strategic choices 93
- 5.1.3.4.3 Weaknesses & competitive threats 93
- 5.1.4 SANOFI 94
- 5.1.4.1 Business overview 94
- 5.1.4.2 Products offered 95
- 5.1.4.3 Recent developments 96
- 5.1.4.3.1 Product launches and approvals 96
- 5.1.4.3.2 Expansions 96
- 5.1.4.3.3 Other developments 97
- 5.1.4.4 MnM view 97
- 5.1.4.4.1 Right to win 97
- 5.1.4.4.2 Strategic choices 97
- 5.1.4.4.3 Weaknesses & competitive threats 98
- 5.1.5 ELI LILLY AND COMPANY 99
- 5.1.5.1 Business overview 99
- 5.1.5.2 Products offered 100
- 5.1.5.3 Recent developments 101
- 5.1.5.3.1 Product launches and approvals 101
- 5.1.5.3.2 Deals 101
- 5.1.5.3.3 Expansions 102
- 5.1.5.3.4 Other developments 102
- 5.1.5.4 MnM view 103
- 5.1.5.4.1 Right to win 103
- 5.1.5.4.2 Strategic choices 103
- 5.1.5.4.3 Weaknesses and competitive threats 103
- 5.1.6 TANDEM DIABETES CARE, INC. 104
- 5.1.6.1 Business overview 104
- 5.1.6.2 Products offered 105
- 5.1.6.3 Recent developments 106
- 5.1.6.3.1 Product launches and approvals 106
- 5.1.6.3.2 Deals 107
- 5.1.7 INSULET CORPORATION 108
- 5.1.7.1 Business overview 108
- 5.1.7.2 Products offered 109
- 5.1.7.3 Recent developments 109
- 5.1.7.3.1 Product launches and approvals 109
- 5.1.7.3.2 Deals 111
- 5.1.7.3.3 Expansions 112
- 5.1.7.3.4 Other developments 112
- 5.1.8 BIOCON 113
- 5.1.8.1 Business overview 113
- 5.1.8.2 Products offered 114
- 5.1.8.3 Recent developments 115
- 5.1.8.3.1 Deals 115
- 5.1.8.3.2 Other developments 115

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.1.9	ROCHE DIABETES CARE	116
5.1.9.1	Business overview	116
5.1.9.2	Products offered	117
5.1.9.3	Recent developments	118
5.1.9.3.1	Product launches and approvals	118
5.1.10	HTL-STREFA (SUBSIDIARY OF THE MTD GROUP)	119
5.1.10.1	Business overview	119
5.1.10.2	Products offered	120
5.1.10.3	Recent developments	120
5.1.10.3.1	Deals	120
5.1.11	YPSOMED	121
5.1.11.1	Business overview	121
5.1.11.2	Products offered	122
5.1.11.3	Recent developments	123
5.1.11.3.1	Product launches and approvals	123
5.1.11.3.2	Deals	124
5.1.11.3.3	Expansions	125
5.1.11.3.4	Other developments	126
5.1.12	MEDTRUM TECHNOLOGIES INC.	127
5.1.12.1	Business overview	127
5.1.12.2	Products offered	127
5.1.13	TERUMO CORPORATION	128
5.1.13.1	Business overview	128
5.1.13.2	Products offered	129
5.1.13.3	Recent developments	130
5.1.13.3.1	Product launches and approvals	130
5.1.13.3.2	Deals	130
5.1.13.3.3	Expansions	131
5.1.13.3.4	Other developments	131
5.1.14	WOCKHARDT LIMITED	132
5.1.14.1	Business overview	132
5.1.14.2	Products offered	133
5.1.14.3	Recent developments	133
5.1.14.3.1	Product launches and approvals	133
5.1.14.3.2	Other developments	134
5.1.15	NIPRO	135
5.1.15.1	Business overview	135
5.1.15.2	Products offered	136
5.1.15.3	Recent developments	137
5.1.15.3.1	Expansions	137
5.2	OTHER PLAYERS	138
5.2.1	CEQUR CORPORATION	138
5.2.2	EOFLOW CO., LTD.	139
5.2.3	HINDUSTAN SYRINGES & MEDICAL DEVICES LTD	140
5.2.4	SOOIL DEVELOPMENTS CO., LTD	141
5.2.5	SUNGSHIM MEDICAL CO., LTD.	142
5.2.6	B.BRAUN SE	143

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.7	DEBIOTECH SA	144
5.2.8	JIANGSU DELFU MEDICAL DEVICE CO., LTD	144
5.2.9	HASELMEIER (A SUBSIDIARY OF MEDMIX)	146
5.2.10	MANNKIND CORPORATION	147
6	APPENDIX	148
6.1	RESEARCH METHODOLOGY	148
6.1.1	RESEARCH DATA	148
6.1.1.1	Secondary data	148
6.1.1.2	Primary data	149
6.1.2	ASSUMPTIONS FOR STUDY	150
6.1.3	RESEARCH LIMITATIONS	150
6.1.4	RISK ASSESSMENT	151
6.2	COMPANY EVALUATION MATRIX: METHODOLOGY	151
6.3	AUTHOR DETAILS	154

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Insulin Delivery Device - Company Evaluation Report, 2025

Market Report | 2025-08-01 | 154 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$2650.00
	Corporate License	\$4250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com